ABO and Rh Blood Group Frequencies in Acute Leukemia Patients
NCT07108010 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2025-08-06
Summary
This retrospective observational study aims to evaluate the distribution of ABO and Rh blood groups among patients diagnosed with acute leukemia. By analyzing medical records from leukemia cases, the study seeks to identify any potential associations between blood group types and the occurrence of the disease.
Conditions
- Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia)
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
Asmaa Mohamed Zahran, M.D., Professor · South Egypt Cancer Institute, Assiut University
-
Walaa Talaat Kamel, M.D., Lecturer · South Egypt Cancer Institute, Assiut University
-
Esraa Nasr Abd El Hakeem, M.D., Lecturer · Assiut University
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-10-01
- Primary Completion
- 2026-12-30
- Completion
- 2027-04-28
Countries
- Egypt
Study Locations
More Related Trials
-
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.
NCT05383014 ·Status: UNKNOWN
-
Expression of TET1 Gene in Acute Leukaemia
NCT03267485 ·Status: UNKNOWN
-
CD155 Expression in Acute Myeloid Leukemia
NCT06369662 ·Status: COMPLETED
-
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
NCT06580106 ·Status: RECRUITING
-
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
NCT03030612 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
NCT01311258 ·Status: RECRUITING
-
D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia
NCT06188182 ·Status: NOT_YET_RECRUITING
-
The Prognostic Significance of Platelet to White Blood Cell Ratio (PWR) in Patients With Acute Myeloid Leukemia
NCT07115537 ·Status: NOT_YET_RECRUITING
-
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia
NCT04215822 ·Status: UNKNOWN
-
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
NCT05042531 ·Status: UNKNOWN ·Phase: NA
-
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
NCT02084563 ·Status: COMPLETED ·Phase: PHASE2
-
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
NCT04842604 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)
NCT00926731 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
NCT04964518 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
NCT00923234 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
NCT02677922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions
NCT07080970 ·Status: NOT_YET_RECRUITING
-
Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT00915252 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
NCT00952588 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML
NCT04490707 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
NCT01265199 ·Status: TERMINATED ·Phase: PHASE1
-
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
NCT00897182 ·Status: COMPLETED
-
Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression
NCT05512104 ·Status: UNKNOWN
-
Red Cell Transfusion Goals in Patients With Acute Leukemias
NCT02086773 ·Status: COMPLETED ·Phase: PHASE1
-
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
NCT01038635 ·Status: COMPLETED ·Phase: PHASE1/PHASE2